Compare Vaxcyte Inc. Common Stock (PCVX) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs Twilio Inc — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while Twilio Inc trades at $268.1 (market cap $43.25B). The key difference: Twilio Inc is far larger — about 4.1× Vaxcyte Inc. Common Stock's market cap, and Vaxcyte Inc. Common Stock is more actively traded (2,644,694 versus 1,616,308). Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and Twilio Inc for 56 Days on average.
| PCVX | TWLO | |
|---|---|---|
Market Cap | $10.51B | $43.25B |
Volume | 2,644,694 | 1,616,308 |
Sector | Health | Technology |
52-Week High | $73.82 | $301.27 |
52-Week Low | $40.32 | $106.23 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $9.14B | $41.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Twilio stock trades at $271.12, down 4.08% today, amid mixed signals. The technical outlook is bullish based on moving averages, with key support at $268. Fundamentally, revenue grew to $5.07B in 2025, with net income turning positive at $33.83M after years of losses. Recent news highlights its upcoming addition to the S&P 500 index effective October 6, 2026, a positive catalyst for institutional interest.
The outlook is cautiously optimistic given strong analyst support (76.9% buy ratings) and a consensus price target of $257.59, though the stock trades above this level. Risks include high valuation multiples (P/E 38.89) and competitive pressures in customer engagement software. Earnings beats in recent quarters support growth momentum, but investors should weigh rich valuations against execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
